Keybank National Association OH decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 230,772 shares of the medical research company’s stock after selling 10,471 shares during the period. Keybank National Association OH’s holdings in Amgen were worth $97,273,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently added to or reduced their stakes in AMGN. State Street Corp raised its holdings in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the last quarter. MW Advisory LLC purchased a new position in shares of Amgen in the second quarter valued at approximately $1,054,000. Baird Financial Group Inc. lifted its position in shares of Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after acquiring an additional 5,496 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Amgen by 105.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock worth $5,696,000 after acquiring an additional 6,947 shares during the last quarter. Finally, Nilsine Partners LLC acquired a new stake in shares of Amgen in the second quarter worth approximately $3,329,000. Institutional investors and hedge funds own 76.50% of the company’s stock.
More Amgen News
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
- Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
- Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article
Amgen Stock Performance
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same period in the prior year, the business earned $5.64 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. Analysts predict that Amgen Inc. will post 23.33 EPS for the current fiscal year.
Amgen Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. Amgen’s payout ratio is 58.47%.
Analyst Upgrades and Downgrades
AMGN has been the subject of several research reports. Truist Financial boosted their price target on Amgen from $380.00 to $398.00 and gave the stock a “hold” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. raised their price objective on Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Cantor Fitzgerald lifted their target price on shares of Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 4th. Argus lifted their target price on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Finally, Weiss Ratings raised shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $422.76.
Insider Transactions at Amgen
In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is currently owned by insiders.
Amgen Company Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Recommended Stories
- Five stocks we like better than Amgen
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
